Genetic Signatures of HPV-related and Unrelated Oropharyngeal Carcinoma and Their Prognostic Implications

被引:171
作者
Klussmann, Jens P. [1 ]
Mooren, Jeroen J. [4 ,5 ]
Lehnen, Martin [1 ]
Claessen, Sandra M. H. [4 ]
Stenner, Markus [1 ]
Huebbers, Christian U. [1 ,3 ]
Weissenborn, Soenke J. [4 ]
Wedemeyer, Inga [2 ]
Preuss, Simon F. [1 ]
Straetmans, Jos M. J. A. A. [5 ]
Manni, Johannes J. [5 ]
Hopman, Anton H. N. [4 ]
Speel, Ernst-Jan M. [4 ]
机构
[1] Univ Cologne, Dept Otorhinolaryngol Head & Neck Surg, D-50924 Cologne, Germany
[2] Univ Cologne, Dept Pathol, D-50924 Cologne, Germany
[3] Univ Cologne, Jean Uhrmacher Inst, D-50924 Cologne, Germany
[4] Maastricht Univ Med Ctr, Dept Mol Cell Biol, Maastricht, Netherlands
[5] Maastricht Univ Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
关键词
SQUAMOUS-CELL CARCINOMAS; GENOMIC HYBRIDIZATION ANALYSIS; HUMAN-PAPILLOMAVIRUS; NECK-CANCER; TONSILLAR CARCINOMAS; CERVICAL-CANCER; CHROMOSOMAL ALTERATIONS; 11Q13; AMPLIFICATION; INVASIVE CANCER; UNITED-STATES;
D O I
10.1158/1078-0432.CCR-08-1463
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Patients with human papillomavirus (HPV)-containing oropharyngeal squamous cell carcinomas (OSCC) have a better prognosis than patients with HPV-negative OSCC. This may be attributed to different genetic pathways promoting cancer. Experimental Design: We used comparative genomic hybridization to identify critical genetic changes in 60 selected OSCC, 28 of which were associated with HPV-16 as determined by HPV-specific PCR and fluorescence in situ hybridization analysis and positive p16(INK4A) immunostaining. The results were correlated with HPV status and clinical data from patients. Results: Two thirds of OSCC harbored gain at 3q26.3-qter irrespective of HPV status. In HPV-negative tumors this alteration was associated with advanced tumor stage (P = 0.013). In comparison with HPV-related OSCC, the HPV-negative tumors harbored: (a) a higher number of chromosomal alterations and amplifications (P = 0.03 and 0.039, respectively); (b) significantly more losses at 3p, 5q, 9p, 15q, and 18q, and gains/amplifications at 11q13 (P = 0.002, 0.03; <0.001, 0.02, 0.004, and 0.001, respectively); and (c) less often 16q losses and Xp gains (P = 0.02 and 0.03). Survival analysis revealed a significantly better disease-free survival for HPV-related OSCC (P = 0.02), whereas chromosome amplification was an unfavorable prognostic indicator for disease-free and overall survival (P = 0.01 and 0.05, respectively). Interestingly, 16q loss, predominantly identified in HPV-related OSCC, was a strong indicator of favorable outcome (overall survival, P = 0.008; disease-free survival, P = 0.01) and none of these patients had a tumor recurrence. Conclusions: Genetic signatures of HPV-related and HPV-unrelated OSCC are different and most likely underlie differences in tumor development and progression. In addition, distinct chromosomal alterations have prognostic significance.
引用
收藏
页码:1779 / 1786
页数:8
相关论文
共 66 条
  • [61] Veltman JA, 2001, INT J CANCER, V91, P193, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1029>3.3.CO
  • [62] 2-5
  • [63] Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract
    Wentzensen, N
    Vinokurova, S
    Doeberitz, MV
    [J]. CANCER RESEARCH, 2004, 64 (11) : 3878 - 3884
  • [64] Imiquimod treatment of anal Intraepithelial neoplasia in HIV-positive men
    Wieland, Ulrike
    Brockmeyer, Norbert H.
    Weissenborn, Soenke J.
    Hochdorfer, Bettina
    Stuecker, Markus
    Swoboda, Jochen
    Altmeyer, Peter
    Pfister, Herbert
    Kreuter, Alexander
    [J]. ARCHIVES OF DERMATOLOGY, 2006, 142 (11) : 1438 - 1444
  • [65] Wittekindt C, 2005, ADV OTO-RHINO-LARYNG, V62, P72
  • [66] Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck
    Wreesmann, VB
    Shi, W
    Thaler, HT
    Poluri, A
    Kraus, DH
    Pfister, D
    Shaha, AR
    Shah, JP
    Rao, PH
    Singh, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (19) : 3965 - 3972